报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月，据medical design and outsourcing网站报道，捷迈邦美Zimmer Biomet披露了其首席执行官、其他高管以及普通员工的薪酬变动，预计均有 所上涨。与此同时，GE医疗公布其高管以及普通员工的薪酬均有所下降。 2024年Zimmer Biomet 薪酬最高的高管是总裁兼首席执行官 Ivan Tornos，年薪为 1500万美元 ，其中包括120万美元的薪水、1180万美元的股票奖励和170万美 元的奖金。Ivan Tornos还获得了价值26万美元各类补贴，总薪酬比前一年的1020万美元 上 涨47%。 Suketu Upadhyay：首席财务官兼财务、运营以及供应链执行副总裁 # 捷迈邦美高管 薪酬 排名 Ivan Tornos：总裁兼首席执行官 年薪为 5 90万美元 ，其中包括87.6万美元的薪水、400万美元的股票奖励和82.09万美元的奖金等，此外获得价值18万美元左右的各类补贴，总薪酬较上 一年的1040万美元 下降43%。 Wilfre ...

Core Viewpoint - Zimmer Biomet Holdings, Inc. will host its first quarter earnings conference call on May 5, 2025, at 8:30 a.m. ET, with a news release detailing the quarterly results available at 6:30 a.m. ET on the same day [1] Company Overview - Zimmer Biomet is a global leader in medical technology, focusing on maximizing mobility and improving health through innovative products and integrated digital and robotic technologies [3][4] - The company has over 90 years of experience and is committed to delivering high-quality solutions to patients and providers [4] Conference Call Details - U.S. and Canada participants can join the conference call by dialing (888) 204-4368 with conference ID 5103691, while international callers should dial +1 (323) 994-2093 using the same conference ID [2]

Zimmer Biomet’s (ZBH) strategic priorities, new product launches and focus on international expansion bolster our confidence in this stock. Yet, the difficult macroeconomic situation and leveraged capital structure are concerning. The stock carries a Zacks Rank #3 (Hold).Favorable Factors For ZBHDespite challenging market conditions in the form of pricing pressure, the last few quarters witnessed gradual stability in the global musculoskeletal market with better-than-expected sales growth in certain geograp ...

Expanding Thoracic Portfolio With the CE Mark, Zimmer Biomet will make the RibFix Advantage Fixation System available in the European Economic Area (EEA) and other markets that recognize the CE Mark. RibFix Advantage Fixation System For more information on the RibFix Advantage Fixation System watch the animation. About Zimmer Biomet With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues t ...

Industry Overview - The surgical robotics market is experiencing rapid growth, driven by advances in minimally invasive surgery, with a market value of $11.48 billion in 2024 and a projected compound annual growth rate of 12.4% from 2025 to 2030 [2] - Key growth drivers include the integration of AI, which enhances precision and reduces complications, and the increasing demand for robotic surgeries due to an aging global population [6][7] Major Areas of Growth - Minimally invasive surgery is a significant factor driving the adoption of surgical robotics, providing benefits such as precision, smaller incisions, and faster recovery times across various fields including urology, gynecology, orthopedics, and general surgery [5] - The aging population is increasing the demand for robotic surgery systems, as these systems offer improved precision and lower risks for older patients [7] Company Analysis Intuitive Surgical - Intuitive Surgical's da Vinci surgical system has been a key performance driver since its launch, offering minimally invasive surgery and supporting rapid adoption through an integrated ecosystem [9] - The company has a long-term expected EPS growth rate of 16.1%, with projected revenue growth of 14.4% for 2025 [10] Zimmer Biomet - Zimmer Biomet is focusing on expanding its ROSA Robotics portfolio, which includes systems for knee, hip, and shoulder surgeries, enhancing the surgical experience [11][12] - The company has a projected sales growth rate of 2.6% for 2025, with a favorable current cash flow rate of 3.6% [13] Stereotaxis - Stereotaxis is expanding its global presence and has achieved regulatory approvals for its next-generation robotic system, GenesisX, enhancing its competitive position [14] - The company has a projected sales growth rate of 26.3% for 2025, with a favorable current cash flow rate of 13.1% [15]

Zimmer Biomet Holdings, Inc. (ZBH) is participating in the ongoing American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego, from March 10-14. Here, the company is highlighting advancements in hip, knee, and upper extremity reconstruction, as well as its latest ambulatory surgery center (ASC) solutions.Expanding Hip Reconstruction PortfolioAt AAOS 2025, Zimmer Biomet is presenting its comprehensive hip portfolio, with the primary focus being on the Z1 Triple-Taper Femoral Hip System, ...

报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月7日， 捷迈邦美Zimmer Biomet （纽约证券交易所代码：ZBH）宣布，其 Persona Revision SoluTion Femur（股骨）膝关节植入物组件 已获得美国食品药品监督管理局（FDA）的510(k)许可。 该组件是 Persona膝关节翻修系统（Persona Revision Knee System） 的一部分，为某些金属敏感的患者提 供了一种替代方案。它采用了一种专有的表面硬化处理技术，旨在提高耐磨性能。该产品为外科医生提供了一 系列解剖组件，包括胫骨和股骨锥，以及多种茎选择，以解决区域固定问题。 合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 # 产品介绍 皮肤金属过敏影响着10%-15%的普通人群，而带有金属植入物的患者中这一比例可能高达25%。当患者接 触到某些常用于金属膝关节植入物的金属时，可能会出现炎症反应、疼痛和植入物松动等问题。 而 Persona Revision SoluTion Femur膝关节植入物 是一款专为膝关节翻修手术 ...

Core Viewpoint - Zimmer Biomet (ZBH) is experiencing growth driven by strong procedural performance, effective execution, and innovation momentum, although the stock is facing challenges from a tough macroeconomic environment that has increased expenses [1] Group 1: Growth Factors - The company is focusing on strengthening its presence in both developed and emerging international markets, which are expected to provide long-term growth opportunities [2] - Strong revenue growth in the Asia Pacific market has been noted, supported by product launches and customer adoption [3] - The global musculoskeletal market has shown gradual stability, with improved sales growth in certain regions due to favorable demographics and increased healthcare utilization [4] Group 2: Financial Performance - In Q4 2024, Zimmer Biomet reported growth in large joints, with global sales for Knees, Hips, and S.E.T. increasing by 5.6%, 4%, and 8.4% respectively at constant exchange rates [5] - Over the past three months, ZBH shares have increased by 0.7%, while the industry has grown by 4.6% [6] Group 3: Challenges - Industry-wide staffing shortages and supply chain issues are negatively impacting growth [7] - High policy rates and geopolitical complications are affecting raw material and labor costs, as well as freight charges [8] - The company is facing reimbursement challenges in the Restorative Therapies business and acute supply challenges in Sports and Trauma, which are pressuring revenues and operating profits [8] Group 4: Cost and Margin Analysis - In Q4, the cost of products sold increased by 5.1%, and selling, general, and administrative expenses rose by 3.4%, leading to a contraction in adjusted gross margin by 123 basis points and adjusted operating margin by 43 basis points [9] - Projections indicate a 5.7% increase in the cost of products sold and a 4.2% rise in selling, general, and administrative expenses for 2025 [9] Group 5: Foreign Exchange Impact - A significant portion of Zimmer Biomet's revenues comes from Europe and Japan, where the strengthening U.S. dollar has adversely affected operations [10] - In 2024, net sales were impacted by a 1% decline due to foreign exchange rate changes, with expectations of a 1.5%-2% adverse impact on 2025 revenues [11]

Core Insights - Zimmer Biomet Holdings, Inc. is showcasing its diverse orthopedic and musculoskeletal innovations at the AAOS 2025 Annual Meeting, emphasizing its comprehensive hip portfolio and newly launched knee and upper extremities reconstructive technologies [1][2] Hip Reconstruction Technologies - The Z1™ Triple-Taper Femoral Hip System features a triple-taper design with extensive innovations aimed at providing more solutions for a wider range of patients [7] - The HAMMR® Automated Hip Impaction System is designed to reduce surgeon strain and fatigue during procedures [7] - The OrthoGrid Hip AI® technology offers AI-powered tools for intra-operative assistance in achieving optimal surgical outcomes [7] - The HipInsight™ System is the first FDA-cleared mixed reality system for hip navigation, utilizing Microsoft HoloLens 2 for real-time guidance [7] Knee Reconstruction Technologies - The Persona® Revision SoluTion™ Femur is a newly cleared revision knee implant component, providing an alternative for patients with sensitivities to certain metals [7] - The Oxford® Cementless Partial Knee is the only FDA-approved cementless partial knee implant in the U.S., known for its efficiency and longevity [7] - The Persona® OsseoTi® Keel Tibia is a cementless anatomic tibia designed for stable fixation and intra-operative versatility [7] - The Persona IQ® 30 mm Stem is the world's only smart knee implant that collects data for post-operative recovery insights [7] Upper Extremities Technology - The OsseoFit™ Stemless Shoulder System is designed for stable fixation by optimizing anatomic fit for stemless shoulder arthroplasty [5] ASC Solutions - The ZBX™ program offers a comprehensive ASC solution tailored to the needs of surgeons, enhancing efficiency in the operating room [6]

Core Viewpoint - Zimmer Biomet Holdings, Inc. has received FDA 510(k) clearance for the Persona® Revision SoluTion™ Femur, a knee implant designed for patients with metal sensitivities, marking a significant advancement in the revision knee implant market [1][2]. Product Details - The Persona Revision SoluTion Femur is part of the Persona Revision Knee System and utilizes a proprietary surface-hardening treatment to enhance wear performance [1][2]. - This new implant is made from a proprietary Tivanium® (Ti-6Al-4V) alloy, which has over 17 years of clinical use, and is treated with the Ti-Nidium Surface Hardening Process to improve material strength and wear resistance [2][3]. - The implant will be available in standard and plus sizes to accommodate various patient needs, particularly addressing flexion instability and soft tissue balancing [2][3]. Market Context - Metal hypersensitivity affects 10-15% of the general population, with prevalence in patients with metallic implants reaching up to 25%, indicating a significant market need for alternatives to traditional metal implants [2][3]. - The Persona Revision SoluTion Femur is positioned as the first metal alternative option for patients with sensitivities to common metal allergens such as nickel, cobalt, and chromium [2][3]. Company Overview - Zimmer Biomet is recognized as a global leader in medical technology, focusing on maximizing mobility and improving health through innovative products and integrated digital technologies [3][4]. - The company has a legacy of over 90 years in the industry, emphasizing a culture of evolution and innovation to deliver high-quality solutions [4].